

# Diagnostic Screening Workflow for Mutations in the *BRCA1* and *BRCA2* Genes

Stella Lai, Clare Brookes, Debra O. Prosser, Chuan-Ching Lan, Elaine Doherty, \*Donald R. Love

## سير عمل التحري التشخيصي لطفرات جينات *BRCA1* و *BRCA2*

ستيلا لاي، كلير بروكس، ديبورا أو بروسر، شوان-شينج لان، إلين دوهيرتي ودونالد ر. لوف

**ABSTRACT: Objectives:** Screening for mutations in large genes is challenging in a molecular diagnostic environment. Sanger-based DNA sequencing methods are largely used; however, massively parallel sequencing (MPS) can accommodate increasing test demands and financial constraints. This study aimed to establish a simple workflow to amplify and screen all coding regions of the *BRCA1* and *BRCA2* (*BRCA1/2*) genes by Sanger-based sequencing as well as to assess a MPS approach encompassing multiplex polymerase chain reaction (PCR) and pyrosequencing. **Methods:** This study was conducted between July 2011 and April 2013. A total of 20 patients were included in the study who had been referred to Genetic Health Services New Zealand (Northern Hub) for *BRCA1/2* mutation screening. Patients were randomly divided into a MPS evaluation and validation cohort (n = 10 patients each). Primers were designed to amplify all coding exons of *BRCA1/2* (28 and 42 primer pairs, respectively). Primers overlying known variants were avoided to circumvent allelic drop-out. The MPS approach necessitated utilisation of a complementary fragment analysis assay to eliminate apparent false-positives at homopolymeric regions. Variants were filtered on the basis of their frequency and sequence depth. **Results:** Sanger-based sequencing of PCR-amplified coding regions was successfully achieved. Sensitivity and specificity of the combined MPS/homopolymer protocol was determined to be 100% and 99.5%, respectively. **Conclusion:** In comparison to traditional Sanger-based sequencing, the MPS workflow led to a reduction in both cost and analysis time for *BRCA1/2* screening. MPS analysis achieved high analytical sensitivity and specificity, but required complementary fragment analysis combined with Sanger-based sequencing confirmation in some instances.

**Keywords:** Massively Parallel Sequencing; *BRCA1* Gene; *BRCA2* Gene; HBOC Syndrome; Detection, heterozygote.

**الملخص: الهدف:** يصعب في بيئة التشخيص الجزيئي تحري الطفرات في الجينات الكبيرة. وعادة ما يقاس تسلسل الحمض النووي بطرق سانقر. غير أن طرق التسلسل الموازي واسع النطاق (MPS) يمكنها استيعاب الطلب المتزايد من القياسات تحت ظروف قيود مالية كبيرة. تهدف هذه الدراسة إلى تقديم خطة سير عمل تضخيم وتحري كل مناطق الشفرات في جينات *BRCA1* و *BRCA2* بواسطة طريقة سانقر وكذلك تقييم طريقة MPS التي تشمل تفاعل البلمرة المتسلسل (PCR) وسلسلة البايرو. الطريقة: أجريت هذه الدراسة بين يوليو 2011 وأبريل 2013، وشملت 20 مريضاً تم تحويلهم إلى الخدمات الصحية الوراثية في نيوزلندا (المحور الشمالي) لتحري طفرات *BRCA1/2*. وتم تقسيم المرضى عشوائياً لقسمين متساويين، قسم لتقييم طرق الـ MPS، وقسم لتوثيق المصادقة. وتم تحديد مناطق بدء العمل لتضخيم شفرة كل أكسونات (محاورات) جينات *BRCA1* و *BRCA2* (28 و 42 زوجاً من مناطق بدء العمل، على التوالي). وتم تحاشي مناطق العمل التي تعلق المتغيرات المعروفة للروغان من الأسقاط الأليلي. وتطلب استخدام طرق الـ MPS استعمال مقاييس مكملة لتحليل الشدة حتى يمكن التخلص من النتائج الإيجابية الكاذبة الظاهرية حول المناطق البلمورية المتماثلة. وتم ترشيح (فلتر) المتغيرات بناء على تواترها وتسلسل عمقها. **النتائج:** تم بنجاح قياس الشفرات بواسطة تسلسل الحمض النووي المضخم بواسطة الـ PCR والمبني على طريقة سانقر. وبلغت نسبتا الحساسية والنوعية لطريقة MPS 100% و 99.5%، على التوالي. **الخلاصة:** عند المقارنة مع طريقة سانقر التقليدية لقياس التسلسل نجد أن بإمكان سير عمل الـ MPS أن يقلل تكلفة التحري التشخيصي لـ *BRCA1/2* ويختصر من زمنه. ويمتاز تحليل الـ MPS بنسبة عالية من الحساسية والنوعية، إلا أنه يتطلب في بعض الحالات استخدام مقاييس مكملة لتحليل الشدة إضافة إلى التثبت بواسطة التسلسل المبني على طريقة سانقر.

**مفتاح الكلمات:** طرق التسلسل الموازي واسع النطاق: جين *BRCA1*: جين *BRCA2*: متلازمة HBOC: اكتشاف: زيجوت متغيرة الألائل.

### ADVANCES IN KNOWLEDGE

- The research described in this study allows for capillary-based sequencing as well as massively parallel sequencing (MPS) of the *BRCA1* and *BRCA2* (*BRCA1/2*) genes for disease-causing mutations in patients with apparent hereditary breast and ovarian cancer.
- The results of this study have determined parameters for assessing sequence quality in order to reduce the number of false-positive calls using MPS and a pyrosequencing platform.

### APPLICATION TO PATIENT CARE

- The use of MPS enables sequence-detectable mutations to be identified quickly, which is a significant advantage to all patients, regardless of their results.
- Furthermore, the MPS approach used in the current study was found to improve turn-around time for screening *BRCA1/2* genes and reduce the cost of diagnostic screening.

CONVENTIONAL SANGER DIDEOXYNUCLEOTIDE (ddNTP) DNA sequencing is the most commonly used method of routine mutation screening.<sup>1–3</sup> This method was developed in the 1970s and has become the gold standard for diagnostic sequencing.<sup>1,4</sup> However, the cost of Sanger-based sequencing is relatively high and the procedure is time-consuming, making it impractical for screening large genes such as *BRCA1* and *BRCA2* (*BRCA1/2*).

The increasing demand for diagnostic genetic testing in a clinical setting has created the need for an alternative technology that can accommodate high throughput, while reducing costs and turnaround times. The development of massively parallel sequencing (MPS), also known as next-generation sequencing, enables the sequencing of millions of DNA fragments in a single run.<sup>5,6</sup> MPS technology has been readily adopted in research settings and has recently moved into the diagnostic environment; however, this has led to issues regarding sequence quality parameters and the need for comprehensive bioinformatic analysis.

In New Zealand, breast cancer is the most frequently registered cancer and the second leading cause of cancer-related deaths among women. Compared to the second half of last century, the incidence of breast cancer has increased in New Zealand.<sup>7</sup> Germline mutations in the *BRCA1/2* genes account for approximately 10–15% of all breast and ovarian cancers; these are known as hereditary breast and ovarian cancers (HBOC).<sup>8,9</sup> The *BRCA1/2* genes, which were identified by positional cloning during the 1990s, encode for proteins that are responsible for controlling cellular growth and differentiation.<sup>8</sup>

The majority of germline mutations in the *BRCA1/2* genes are either nonsense or frame-shift mutations, which result in truncated proteins.<sup>8,9</sup> Exonic deletions or duplications have also been reported but are rare. In view of the above, together with the large number of reported mutations, screening the coding regions of the *BRCA1/2* genes for mutations has largely involved denaturing high-performance liquid chromatography or direct sequencing.<sup>10–14</sup> In contrast, targeted mutation analysis using conventional Sanger-based sequencing is a common initial testing strategy for individuals of Ashkenazi Jewish ancestry with HBOC. Three founder mutations have been described in this population: c.68\_69delAG and c.5266dupC in the *BRCA1* gene and c.5946delT in the *BRCA2* gene, with a combined frequency of approximately 2%.<sup>15,16</sup> The *BRCA1/2* genes are classic examples of the difficulties commonly encountered in a diagnostic setting: they are large autosomal genes with a wide spectrum of mutations, rich in homopolymeric regions and are

highly polymorphic, complicating primer designs for polymerase chain reaction (PCR) amplification.<sup>17</sup>

The objective of this study was to investigate the diagnostic potential of the more cost-effective MPS approach in screening for mutations in the *BRCA1/2* genes, compared to conventional Sanger-based sequencing. This strategy involved a pyrosequencing approach in order to develop a rapid, inexpensive and rigorous assay for identifying disease-causing mutations in the *BRCA1/2* genes.

## Methods

This study was carried out between July and April 2013. A total of 20 patients who had been referred to Genetic Health Services New Zealand (Northern Hub) for *BRCA1/2* gene mutation screening were selected for inclusion. Of the patients, 16 carried known disease-causing mutations. These patients carried a range of *BRCA1/2* gene variants, including missense, nonsense, duplication, insertion-deletion and deletion variants. The analysis of whole exon deletion events was excluded from the current study as it concerned only the ability to detect intra-exonic and splice site mutations.

A total of 10 patients were randomly assigned to comprise the MPS evaluation cohort. Genomic DNA from the evaluation group was subjected to two sequencing strategies. The first comprised exon-targeted amplification and subsequent Sanger-based sequencing of the coding regions of *BRCA1/2* while the second comprised the MPS approach described below. A comparison of the latter data against the former allowed MPS analysis parameters to be determined. Identified parameters were then applied to the genomic DNA of the 10 patients in the MPS validation cohort in order to identify sequence variants. Variants were identified using SeqNext, Sequence Pilot software, Version 3.4.2 (JSI Medical Systems GmbH, Kippenheim, Germany). All identified variants, as well as amplicons with insufficient coverage (set at 30x coverage), were subjected to Sanger-based sequencing to determine the sensitivity and specificity of the MPS approach. A fragment analysis approach was also used in conjunction with MPS to reduce the frequency of the false-positive (FP) calls that required Sanger-based sequencing confirmation.

DNA was extracted from peripheral ethylenediaminetetraacetic acid (EDTA) blood samples using the Gentra® Puregene® Blood Kit (3 mL) (Qiagen, Venlo, Limburg, Netherlands), according to the manufacturer's instructions. These DNA samples were assessed by an accredited overseas laboratory to validate the local gene screening strategy used in the study.

In order to offer local *BRCA1/2* gene screening, primers were designed for the simple amplification of all coding regions of the two genes. The design process used, which allows for amplification using a standard reaction condition and cycling protocol, has been previously described.<sup>18</sup> Critically, the primer designs involved extensive analysis of the Single Nucleotide Polymorphism Database (dbSNP)<sup>19</sup> and an iterative design process in order to ensure that primers did not overlie known single nucleotide polymorphisms (SNPs) using SNPCheck (National Genetics Reference Laboratory, Manchester, UK).<sup>20</sup> In the case of Sanger-based sequencing, 70 pairs of primers were designed to flank all of the coding and adjacent splice junction regions of the *BRCA1/2* genes for PCR amplification [Appendix 1].<sup>21,22</sup> In total, 140 fragments were generated with amplicon lengths of 218–745 base pairs (bp). The amplicon lengths were short enough to allow complete bi-directional sequencing of the coding regions of the *BRCA1/2* genes. In order to allow the unambiguous sequencing of amplicons containing repetitive sequences, eight nested primers were also designed [Appendix 2].

The coding regions of the *BRCA1/2* genes were then amplified in a reaction volume of 25 µL containing 50 ng of genomic DNA, 0.4 mM of ddNTP (GE Healthcare Ltd., Little Chalfont, UK), 0.8 µM each of forward and reverse primers, 2 mM of magnesium chloride (MgCl<sub>2</sub>) and one unit of PCR reaction buffer without MgCl<sub>2</sub> together with one unit of FastStart Taq DNA Polymerase (Roche Applied Science, Penzberg, Upper Bavaria, Germany). The thermal cycling conditions consisted of a denaturation step of 95 °C for five minutes, 35 cycles of 94 °C for 45 seconds, 60 °C for 30 seconds and 72 °C for 30 seconds, followed by a final extension of 72 °C for 10 minutes. Purification of each 5 µL of PCR product was performed using USB<sup>®</sup> ExoSAP-IT<sup>®</sup> (Affymetrix Inc., Santa Clara, California, USA). The purified PCR product was then diluted to 2.5 ng per 100 bp and sequenced bi-directionally using M13 forward and reverse primers and BigDye<sup>®</sup> Terminator Version 3.1 Cycle Sequencing Kit (Applied Biosystems, Life Technologies, Thermo Fisher Scientific Corp., Carlsbad, California, USA). Sequenced products (5 µL) were purified using the BigDye<sup>®</sup> XTerminator<sup>™</sup> Purification Kit (Applied Biosystems) and then subjected to capillary electrophoresis using a 3130xl Genetic Analyser (Applied Biosystems) with a 50 cm capillary array. Sequence traces were analysed using KB<sup>™</sup> Basecaller Sequencing Analysis Software, Version 1.4, and Variant Reporter<sup>™</sup> Software, Version 1.0 (Applied Biosystems), with a minimum trace score of 35, which corresponds to an average FP base call frequency of 0.031%.

MPS library amplification involved the amplification of the coding regions of the *BRCA1/2* genes using the BRCA MASTR<sup>™</sup> Dx assay (Multiplicom, Niel, Belgium) in a reaction volume of 15 µL containing 50 ng of genomic DNA. This molecular diagnostic assay allows for multiplex PCR amplification of 93 amplicons in five separate PCRs for each patient. The thermal cycling conditions consisted of a denaturation step of 95 °C for 10 seconds, 20 cycles consisting of 95 °C for 45 seconds, 60 °C for 45 seconds and 68 °C for two minutes, followed by a final extension of 72 °C for 10 minutes.

Secondary PCR used the 454 MID Dx kit (Multiplicom) to tag the amplicons with patient-specific molecular barcodes and 454 sequencing adaptors (A and B) for downstream sequencing. The multiplex identifier (MID) sequences consist of six unique nucleotides and are used to index each *BRCA* library, allowing multiple patient libraries to be multiplexed in a single MPS run. The primary PCR products were diluted in sterile water (1:1000) and 1 µL of this product was used as a template for the secondary PCR with indexing adapters in a total reaction volume of 25 µL. The thermal cycling conditions consisted of a denaturation step at 98 °C for 10 seconds, 20 cycles consisting of 95 °C for 45 seconds, 64 °C for 45 seconds and 68 °C for two minutes, followed by a final extension of 72 °C for 10 minutes.

Subsequent pooling of tagged amplicons for each patient was followed using a predefined mixing protocol (Multiplicom). Each patient's amplicon-pooled library was purified using Agencourt AMPure XP (Beckman Coulter Inc., Beverly, Massachusetts, USA) to remove small residual DNA fragments such as primer dimers. The concentration of each patient's amplicon-pooled library was determined using QuantiT<sup>™</sup> PicoGreen<sup>®</sup> dsDNA Reagent and Assay Kit (Invitrogen, Life Technologies) and normalised to 10 nM in Tris-EDTA buffer (pH 8). In each experiment, five patients' amplicon-pooled libraries were pooled in an equimolar ratio to generate a sequencing library, which contained a total of 465 amplicons for sequencing on the MPS platform.

Emulsion PCR using the GS Junior Titanium emPCR Lib-A Kit (Roche Diagnostics Corp., Indianapolis, Indiana, USA) was performed to clonally amplify single DNA molecules in their own micro-reactors. This was achieved by hybridising the DNA library onto primer-coated beads together with emulsification through vigorous shaking of an oil-water mixture and amplification reagents to achieve emulsion micro-reactors. After subsequent PCR amplification, the micro-reactors were broken and

**Table 1:** Custom settings applied to SeqNext, Sequence Pilot Software, Version 3.4.2 (JSI Medical Systems GmbH, Kippenheim, Germany) to identify sequence variants in the genomic DNA of 10 patients

Setting	Parameter
Analyse/ignore region: minimum absolute coverage	Off
Low coverage warning	30
Mutations: minimum absolute coverage	Off
Mutations: minimum % coverage	20% per direction
Mutations sorting: distinct/other % coverage	20% per direction
Mutations sorting: distinct/homopolymer coverage	35% per direction

DNA-positive beads were deposited onto a picotiter plate for subsequent pyrosequencing.

Data processing was carried out using a predefined amplicon pipeline program, Genome Sequencer Run Processor (Roche Applied Science). Sequence data were aligned against the reference sequences NC\_000017.10 (NM\_007294.3; *BRCA1*) and NC\_000013.10 (NM\_000059.3; *BRCA2*) from the Human Genome Assembly (HG19; Genome Bioinformatics Group, University of California Santa Cruz, USA). Nomenclature from the Human Genome Variation Society (HGVS), Version 2.0,<sup>23</sup> was used to describe all variants with nucleotide numbering starting from the first nucleotide of the translated sequence. Amplicons with flanking regions of 3–20 bp upstream and downstream were analysed using SeqNext. Settings were customised to achieve a Phred quality score equivalent to 33, as described in others studies.<sup>24–26</sup> SeqNext sorts the sequence data for each patient according to the attached MID and variant calling is achieved based on a defined variant frequency, which was set at 20%. As pyrosequencing errors commonly arise in homopolymeric regions, a secondary threshold for these regions of 35% was set to filter out apparent FPs. Currently, a minimum read depth of 20x is widely adopted in research settings as not all targeted regions are evenly sequenced by MPS.<sup>25,27,28</sup> This threshold, termed the minimum base coverage threshold, is necessary in order to avoid possible variant miscalling.<sup>29</sup> The minimum base coverage threshold was set at 30x (combined forward and reverse reads) [Table 1]. An initial variant frequency (VF) of 20% allowed reliable variant calling. Subsequent VF ranges of 40–60% and 90–100% were used for calling heterozygotes and homozygotes, respectively.

*BRCA1/2* genes are homopolymer (HP)-rich and sequencing homopolymeric regions is a known

limitation of pyrosequencing technology which can hamper its effective use.<sup>24,30,31</sup> For this reason, a commercially available fragment analysis assay was used (*BRCA* HP kit, Version 2.0, Multiplicom) to screen for variants in targeted homopolymeric regions in the *BRCA1/2* genes. A fragment analysis approach was used in conjunction with MPS to reduce the frequency of the FP calls that required Sanger-based sequencing confirmation. This assay targets 29 homopolymeric regions (stretches of 6 bp or more) within the coding regions of the *BRCA1/2* genes. Two multiplex PCRs were set up in reaction volumes of 15 µL containing 30 ng of genomic DNA. The thermal cycling conditions consisted of a denaturation step at 98 °C for 10 minutes, 24 cycles consisting of 95 °C for 45 seconds, 60 °C for 45 seconds and 68 °C for two minutes, followed by a final extension of 72 °C for 10 minutes. The PCR products were electrophoresed in the 3130xl Genetic Analyzer and the data were analysed using MAQ-S software, Version 1.4.0 (Multiplicom).

Three strategies were established to reduce the number of FP calls. First, MPS using a pyrosequencing approach required a complementary strategy to screen homopolymeric regions. Regions not covered by the fragment analysis assay were therefore subjected to Sanger-based sequencing. Second, literature searches and bioinformatic splice site analyses using the Berkeley Drosophila Genome Project Program (BDGP)<sup>32,33</sup> were used in the case of intronic single base insertions or deletions occurring in homopoly-meric tracts of ≥6 bp or outside of ±3 bp of the exon-intron boundaries. These putative variants would be filtered out if they were determined highly unlikely to be of pathogenic significance, as reporting them would be of no clinical significance. Third, it was decided not to report variants in the following untranslated regions (UTRs) of the *BRCA2* gene: c.-26G>A (5' UTR) and c.\*105A>C (3' UTR). While these variants are listed in the Breast Cancer Information Core (BIC) database,<sup>34</sup> they have no known clinical significance and thus fall outside the regions of interest (ROI) of the current study. These exclusion strategies were applied to the MPS analysis of the validation cohort.

All patients gave informed consent to be included in this study.

## Results

Sanger-based sequencing was applied to the evaluation cohort (n = 10) who carried a range of *BRCA1/2* gene variants, including missense, nonsense, insertion-deletion and deletion variants. Table 2 summarises the variants that were detected. External laboratory



**Table 2:** Variants detected in the *BRCA1* and *BRCA2* genes of 20 patients using Sanger-based sequencing


Nucleotide	Codon	Type	Patient									
			1	2	3	4	5	6	7	8	9	10
BRCA1												
c.140G>A	p.Cys47Tyr	M							Het*			
c.1067A>G	p.Gln356Arg	M				Het	Het					Het
c.1175_1214del40	p.Leu392Glnfs*5	F		Het*								
c.2077G>A	p.Asp693Asn	M				Het						
c.2082C>T	p.Ser694Ser	S				Het	Het	Het	Hom	Hom		
c.2311T>C	p.Leu771Leu	S				Het	Het	Het	Hom	Hom		
c.2315T>C	p.Val772Ala	M		Het								
c.2612C>T	p.Pro871Leu	M				Het	Het	Het	Hom	Hom		
c.3113A>G	p.Glu1038Gly	M				Het	Het	Het	Hom	Hom		
c.3548A>G	p.Lys1183Arg	M				Het	Het	Het	Hom	Hom		
c.3756_3759delGTCT	p.Ser1253Argfs*10	F			Het*							
c.4065_4068delTCAA	p.Asn1355Lysfs*10	F									Het*	
c.4308T>C	p.Ser1436Ser	S				Het	Het	Het	Hom	Hom		
c.4837A>G	p.Ser1613Gly	M				Het	Het	Het	Hom	Hom		
BRCA2												
c.68-7T>A	-	I										Het
c.865A>C	p.Asn289His	M			Het							
c.1114A>C	p.Asn372His	M	Het			Het	Het	Hom	Het	Het	Het	
c.1365A>G	p.Ser455Ser	S			Het							
c.1395A>C	p.Val465Val	S				Het						
c.2229T>C	p.His743His	S			Het							
c.2971A>G	p.Asn991Asp	M			Het							
c.3396A>G	p.Lys1132Lys	S	Het	Het							Het	Het
c.3807T>C	p.Val1269Val	S		Het			Het		Het			
c.7242A>G	p.Ser2414Ser	S	Het	Het							Het	Het
c.7655_7658delTTAA	p.Ile2552Thrfs*95	F					Het*					
c.7762_7764delATAinsTT	p.Ile2588Phefs*60	F								Het*		
c.7806-14T>C	-	I	Het	Het	Hom	Het		Het		Het	Het	Hom
c.8297delC	p.Thr2766Asnfs*11	F						Het*				
c.8575delC	p.Gln2859Lysfs*4	F										Het*

M = missense; Het = heterozygote; Het\* = heterozygote disease-causing mutation; FS = frame-shift; S = synonymous; Hom = homozygous; I = intronic.

reports on the same DNA samples confirmed the mutations reported.

In total, 128 variants were identified, of which 80 variants were true-positives (TPs) and 48 variants were apparent FPs. The latter were identified by comparing the variant calls against the Sanger-based sequencing data. Of these 48 apparent FPs, 43 lay in homopolymeric regions. Of the 43 apparent FP

variants in homopolymeric regions, 17 were in exons (13 were covered by the BRCA HP kit and four lay in homopolymeric tracts of five bases only) and 26 were in introns. Of the remaining five apparent FPs, three corresponded to the same intronic deletion of one base in a homopolymeric tract that was three bases upstream of a splice acceptor site and two were sequenced at insufficient read depth.



**Figure 1 Panel A & B:** Fragment analysis of homopolymeric regions. **A:** Electropherograms of selected fragments amplified using a commercially available fragment analysis assay. Heterozygotes are identified by arrows. **B:** Sequence electropherograms of the heterozygous regions of the *BRCA1* and *BRCA2* genes shown in panel A. The arrows indicate that length heterozygosity is due to a differing number of adenosines.

The MPS analysis parameters and the exclusion strategies derived from the evaluation cohort were applied to the MPS analysis of the validation cohort ( $n = 10$ ). A total of 115 variants were identified using the MPS analysis parameters; however, 66 calls remained after applying the exclusion strategies. Sanger sequencing confirmed 62 of these 66 calls to be TPs. The remaining four calls were localised to homopolymeric regions not covered by the fragment analysis assay. Importantly, two pathogenic mutations in the *BRCA2* gene (c.1813dupA and c.2957dupA) were not detected by MPS analysis. These mutations occurred in the homopolymeric regions comprising eight and seven adenosines, respectively. However, these two duplications were clearly identified using the fragment analysis assay and MAQ-S software [Figures 1A & B]. The sensitivity and specificity of the combined MPS/HP protocol was determined to be 100% and 99.5%, respectively.


Combining the results of the two cohorts, there were 17 true mutations, 11 FPs that were not filtered out using the exclusion criteria, four with a VF out of the acceptable range and two with insufficient base coverage of less than 30 reads. As two of these confirmations occurred in the same amplicon of one patient, a total of 33 amplicons required sequencing confirmation. A summary of the variants detected in all 20 patients is presented in Appendix 3, together with conclusions regarding their pathogenic status based on the BIC database and the Human Genome Mutation Database (BIOBASE HGMD®

Professional, BIOBASE Biological Databases, Beverly, Massachusetts, USA).<sup>23,34,35</sup> Overall, the sequence data showed variations of approximately 10,000–26,700 total read counts per patient. In terms of read counts per amplicon, the variation was 30–1,900. The Sanger-based sequencing approach achieved a Phred score of 35 with a base call accuracy of 99.97%.

The MPS/HP mutation screening strategy for *BRCA1/2* genes resulted in significant savings in terms of both the cost of consumables and time by three-fold and two-fold, respectively [Appendix 4].

## Discussion

In this study, a simple workflow was established using a benchtop MPS platform to perform comprehensive mutation screening of the *BRCA1/2* genes [Figure 2]. The MPS analysis achieved high analytical sensitivity and specificity, but required complementary fragment analysis combined with Sanger-based sequencing confirmation in some instances. This complementary approach eliminated some of the concerns about the inherent limitations of pyrosequencing technology. The MPS/HP mutation screening strategy for *BRCA1/2* genes resulted in significant savings in terms of both the cost of consumables and time. These advantages are important criteria for diagnostic laboratories.<sup>36</sup> An added advantage of this study was the identification of all variants within the ROI, which comprised the coding regions and flanking 20 bp of the *BRCA1/2* genes.



The quality of sequencing data is the major concern when implementing MPS in a diagnostic setting. The Phred score system has been widely adopted as a quality measure for automated sequencing approaches.<sup>24</sup> Phred scores of 20 for bi-directional sequence data and 30 for uni-directional data have been recommended as rigorous quality control parameters.<sup>37</sup> The Sanger-based sequencing approach utilised had a Phred score of 35 and a 99.97% base call accuracy; it is crucial for a diagnostic laboratory to maintain this score quality when implementing MPS. In order to achieve a similar MPS Phred score, a depth of coverage of 30x and a VF of 20% were implemented. These measures were chosen based on the results of the evaluation cohort and the findings of De Leeneer *et al.*<sup>25</sup>

Also referred to as the allelic fraction, VF is the proportion of individual reads containing the variant call.<sup>25</sup> A VF of 100% for homozygotes and 50% for heterozygotes is ideal. However, cut-off frequencies for heterozygous and homozygous calls have been reported from 23–74% and 78–100%, respectively.<sup>25</sup> According to Jones *et al.*, variant calls of <85% for homozygous variants and <40% for heterozygous variants should be discarded.<sup>38</sup> From the MPS data in the current study, a homozygous variant with a VF of 81% was observed; Sanger-based sequencing determined that this variant was a true heterozygote. Based on Jones *et al.*'s findings, a false-negative result would have been generated if this call was discarded.<sup>38</sup> As a result, cut-off ranges were defined as 90–100% and 40–60% for homozygotes and heterozygotes, respectively. Genotypes of variants that fell outside

of the stated thresholds were confirmed by Sanger-based sequencing.

In the current study, a total of 33 amplicons required sequencing confirmation. However, this sequence load reflects samples that were biased towards positive mutations. In the case of a mutation-negative patient, a Sanger-based sequence load of approximately one amplicon would be expected, which would include the confirmation of any non-pathogenic or missense variants with unknown clinical significance detected for the first time.

The ability to multiplex samples is one of the main advantages of MPS, allowing for cost-effective sequencing with a high sample throughput. The current study was largely confined to analysing five patients per single experiment. An experiment where seven samples were multiplexed was performed to improve cost savings; however, both sensitivity and specificity decreased with less than 10,000 reads generated for each sample. This is lower than the manufacturer's recommendation of 11,000 reads per sample. In addition, the average base coverage was  $106 \pm 58$  bp, which indicated that multiplexing seven samples decreased the confidence of variant calls due to lower coverage across the ROI.

MPS technology is rapidly evolving and further developments and improvements will continue to reduce costs. While the current study has presented an introduction to MPS in the context of a small diagnostic laboratory, the possibility of whole exome sequencing and even whole genome sequencing is attractive, albeit requiring a significant increase in data storage and processing. However, these developments suggest that screening a defined number of genes in a targeted approach, as shown in this study, will be superseded by filtering sequence data to identify variants in a defined gene list that is relevant to the clinical referral.

The validation of the approach described here was limited in scope due to the number of patients analysed; hence, the current study could be considered under-powered.<sup>39</sup> In order to mitigate this feature, further work has been undertaken assessing an additional 70 patients referred for *BRCA1/2* gene sequencing by MPS. These data (not shown here) comprise the identification of approximately 500 variants, all of which are either known exonic and intronic SNPs (averaging seven per patient), known mutations (eight patients) or novel mutations (two patients). All mutations were confirmed as correct by Sanger-based sequencing. Importantly, the exon-specific primer designs have provided a critical resource for the confirmation of variants detected by MPS and for predictive testing. The fact that the

primers do not overlies known SNPs has reduced the likelihood of allelic drop-out.

## Conclusion

In comparison to traditional Sanger-based sequencing, the MPS workflow led to a reduction in cost, analysis time and turn-around time for the screening of *BRCA1/2* genes. The analysis used achieved high analytical sensitivity and specificity, but required complementary fragment analysis combined with Sanger-based sequencing confirmation in some instances. MPS technology is rapidly evolving and further developments and improvements will continue to reduce costs. The current study presented an introduction to MPS in the context of a small diagnostic laboratory.

## APPENDICES

Primer sequences, nested primers for sequencing selected exons, *BRCA1/2* gene variants detected and a brief cost-efficiency analysis of the methods used are available in four supplementary tables included in the online version of this article.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

## References

1. França LT, Carrilho E, Kist TB. A review of DNA sequencing techniques. *Q Rev Biophys* 2002; 35:169–200. doi: 10.1017/S0033583502003797.
2. Metzker ML. Sequencing technologies: The next generation. *Nat Rev Genet* 2010; 11:31–46. doi: 10.1038/nrg2626.
3. Zhou X, Ren L, Meng Q, Li Y, Yu Y, Yu J. The next-generation sequencing technology and application. *Protein Cell* 2010; 1:520–36. doi: 10.1007/s13238-010-0065-3.
4. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 1977; 74:5463–7. doi: 10.1073/pnas.74.12.5463.
5. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, et al. The complete genome of an individual by massively parallel DNA sequencing. *Nature* 2008; 452:872–6. doi: 10.1038/nature06884.
6. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: From basic research to diagnostics. *Clin Chem* 2009; 55:641–58. doi: 10.1373/clinchem.2008.112789.
7. Cunningham R, Shaw C, Blakely T, Atkinson J, Sarfati D. Ethnic and socioeconomic trends in breast cancer incidence in New Zealand. *BMC Cancer* 2010; 10:674. doi: 10.1186/1471-2407-10-674.
8. Taylor MR. Genetic testing for inherited breast and ovarian cancer syndromes: Important concepts for the primary care physician. *Postgrad Med J* 2001; 77:11–15. doi: 10.1136/pmj.77.903.11.
9. Michils G, Hollants S, Dehaspe L, Van Houdt J, Bidet Y, Uhrhammer N, et al. Molecular analysis of the breast cancer genes *BRCA1* and *BRCA2* using amplicon-based massive parallel pyrosequencing. *J Mol Diagn* 2012; 14:623–30. doi: 10.1016/j.jmoldx.2012.05.006.
10. Kim BY, Lee DG, Lee KR, Han SH, Surendran S, Han CW, et al. Identification of *BRCA1* and *BRCA2* mutations from Korean breast cancer patients using denaturing HPLC. *Biochem Biophys Res Commun* 2006; 349:604–10. doi: 10.1016/j.bbrc.2006.08.086.
11. Ou J, Wu T, Sijmons R, Ni D, Xu W, Upur H. Prevalence of *BRCA1* and *BRCA2* germline mutations in breast cancer women of multiple ethnic region in northwest China. *J Breast Cancer* 2013; 16:50–4. doi: 10.4048/jbc.2013.16.1.50.
12. Ratajska M, Brozek I, Senkus-Konefka E, Jassem J, Stepnowska M, Palomba G, et al. *BRCA1* and *BRCA2* point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. *Oncol Rep* 2008; 19:263–8. doi: 10.3892/or.19.1.263.
13. Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, Lariani I, et al. Mutation spectrum and prevalence of *BRCA1* and *BRCA2* genes in patients with familial and early-onset breast/ovarian cancer from Tunisia. *Clin Genet* 2013. doi: 10.1111/cge.12337. [Epub ahead of print].
14. Vuttariello E, Borra M, Calise C, Mauriello E, Greggi S, Vecchione A, et al. A new rapid methodological strategy to assess *BRCA* mutational status. *Mol Biotechnol* 2013; 54:954–60. doi: 10.1007/s12033-012-9646-0.
15. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* among Ashkenazi Jews. *N Engl J Med* 1997; 336:1401–8. doi: 10.1056/NEJM199705153362001.
16. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in *BRCA1* and *BRCA2*. *Nat Genet* 1996; 14:185–7. doi: 10.1038/ng1096-185.
17. Tarabeux J, Zeitouni B, Moncoutier V, Tenreiro H, Abidallah K, Lair S, et al. Streamlined ion torrent PGM-based diagnostics: *BRCA1* and *BRCA2* genes as a model. *Eur J Hum Genet* 2014; 22:535–41. doi: 10.1038/ejhg.2013.181.
18. Doherty E, Marquis-Nicholson R, Love JM, Brookes C, Prosser D, Love DR. Primer design to sequence analysis: A pipeline for a molecular genetic diagnostic laboratory. In: Ivanov O, Ed. *Applications and Experiences of Quality Control*. Rijeka, Croatia: InTech, 2011. Pp. 257–72.
19. National Center for Biotechnology Information. dbSNP. From: [www.ncbi.nlm.nih.gov/snp](http://www.ncbi.nlm.nih.gov/snp) Accessed: Sep 2014.
20. National Genetics Reference Laboratory Manchester. SNPCheck. From: [www.ngrl.org.uk/Manchester/projects/snpcheck](http://www.ngrl.org.uk/Manchester/projects/snpcheck) Accessed: Sep 2014.
21. Messing J. New M13 vectors for cloning. *Methods Enzymol* 1983; 101:20–78. doi: 10.1016/0076-6879(83)01005-8.
22. Yanisch-Perron C, Vieira J, Messing J. Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. *Gene* 1985; 33:103–19. doi: 10.1016/0378-1119(85)90120-9.
23. Human Genome Variation Society (HGVS). Nomenclature for the Description of Sequence Variants. From: [www.hgvs.org/mutnomen](http://www.hgvs.org/mutnomen) Accessed: Sep 2014.
24. Mardis ER. The impact of next-generation sequencing technology on genetics. *Trends Genet* 2008; 24:133–41. doi: 10.1016/j.tig.2007.12.007.
25. De Leeneer K, De Schrijver J, Clement L, Baetens M, Lefever S, De Keulenaer S, et al. Practical tools to implement massive parallel pyrosequencing of PCR products in next generation molecular diagnostics. *PLoS One* 2011; 6:e25531. doi: 10.1371/journal.pone.0025531.



26. Ewing B, Green P. Base-calling of automated sequencer traces using phred: II - Error probabilities. *Genome Res* 1998; 8:186–94. doi: 10.1101/gr.8.3.175.
27. Ellard S, Charlton R, Lindsay H, Camm N, Watson C, Abbs S, et al.; Clinical Molecular Genetics Society. Practice guidelines for Targeted Next Generation Sequencing Analysis and Interpretation. From: [www.cmgsweb.shared.hosting.zen.co.uk/BPGs/BPG%20for%20targeted%20next%20generation%20sequencing%20final.pdf](http://www.cmgsweb.shared.hosting.zen.co.uk/BPGs/BPG%20for%20targeted%20next%20generation%20sequencing%20final.pdf) Accessed: Feb 2014.
28. Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, Corneveaux JJ, et al. Identification of genetic variants using bar-coded multiplexed sequencing. *Nat Methods* 2008; 5:887–93. doi: 10.1038/nmeth.1251.
29. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. *Nat Biotechnol* 2012; 30:1033–6. doi: 10.1038/nbt.2403.
30. Balzer S, Malde K, Lanzén A, Sharma A, Jonassen I. Characteristics of 454 pyrosequencing data: Enabling realistic simulation with flowSim. *Bioinformatics* 2010; 26:420–5. doi: 10.1093/bioinformatics/btq365.
31. Balzer S, Malde K, Jonassen I. Systematic exploration of error sources in pyrosequencing flowgram data. *Bioinformatics* 2011; 27:i304–9. doi: 10.1093/bioinformatics/btr251.
32. Berkeley Drosophila Genome Project (BDGP). Splice Site Prediction by Neural Network. From: [www.fruitfly.org/seq\\_tools/splice.html](http://www.fruitfly.org/seq_tools/splice.html) Accessed: Sep 2014.
33. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. *J Comput Biol* 1997; 4:311–23. doi: 10.1145/267521.267766.
34. National Human Genome Research Institute, National Institutes of Health. Breast Cancer Information Core: An open access on-line breast cancer mutation data base. From: [www.research.nhgri.nih.gov/bic/](http://www.research.nhgri.nih.gov/bic/) Accessed: Sep 2014.
35. BIOBASE Biological Databases. HGMD® Human Gene Mutation Database. From: [www.biobase-international.com/product/hgmd](http://www.biobase-international.com/product/hgmd) Accessed: Sep 2014.
36. Alansari A, Al-Rawahi S, Ba-Omar T, Al-Nabhani M, Date A. The identification of Pompe disease mutations in archival tissues and development of a rapid molecular-based test. *Sultan Qaboos Univ Med J* 2013; 13:502–9.
37. Ellard S, Charlton R, Lindsay H, Camm N, Watson C, Abbs S, et al.; Clinical Molecular Genetics Society. Practice guidelines for Targeted Next Generation Sequencing Analysis and Interpretation. From: [www.cmgsweb.shared.hosting.zen.co.uk/BPGs/BPG%20for%20targeted%20next%20generation%20sequencing%20final.pdf](http://www.cmgsweb.shared.hosting.zen.co.uk/BPGs/BPG%20for%20targeted%20next%20generation%20sequencing%20final.pdf) Accessed: Feb 2014.
38. Jones MA, Bhide S, Chin E, Ng BG, Rhodenizer D, Zhang VW, et al. Targeted polymerase chain reaction-based enrichment and next generation sequencing for diagnostic testing of congenital disorders of glycosylation. *Genet Med* 2011; 13:921–32. doi: 10.1097/GIM.0b013e318226fbf2.
39. Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, et al. A standardized framework for the validation and verification of clinical molecular genetic tests. *Eur J Hum Genet* 2010; 18:1276–88. doi: 10.1038/ejhg.2010.101.

#### Appendix 1: Primer sequences for amplifying the coding regions of the *BRCA1* and *BRCA2* genes

Exon	Forward Primer Sequences	Reverse Primer Sequences
<b><i>BRCA1</i></b>		
2	TGTAACACGACGGCCAGTGGACGTTGTCATTAGTCTTTTGG	CAGGAAACAGCTATGACCAGAGGCAGAGTGGATGGAGA
3	TGTAACACGACGGCCAGTAAATATTGAACGAACCTGAGGC	CAGGAAACAGCTATGACCGGTGTTTCTTGGGTATGAAG
4	TGTAACACGACGGCCAGTGGCTCTTAAGGGCAGTTGTG	CAGGAAACAGCTATGACCAAACCTTCAGGAAAATAACTTTGG
5	TGTAACACGACGGCCAGTTTGATTATAGAGGTTTCTACTGTTGC	CAGGAAACAGCTATGACCAAAAGGTCTTATCAACACGTCATAG
6	TGTAACACGACGGCCAGTTGTCTTAACACAACAAAGAGCATAC	CAGGAAACAGCTATGACCGAGGACTGCTTCTAGCCTGG
7	TGTAACACGACGGCCAGTTTCTCTCAGGAGGAAGAGCAC	CAGGAAACAGCTATGACCTTGGCAAACTATAAGATAAGGAATC
8	TGTAACACGACGGCCAGTCTAGCATTGTACCTGCCACAG	CAGGAAACAGCTATGACCTGCACATACATCCCAGAACC
9	TGTAACACGACGGCCAGTCCCAGCAACCATTTTCAATTC	CAGGAAACAGCTATGACCAACGAAAGGGCAAATATCAG
10-1	TGTAACACGACGGCCAGTGGTTGATTTCACCTCCAAG	CAGGAAACAGCTATGACCCAGACTCCCCATCATGTGAG
10-2	TGTAACACGACGGCCAGTTGCCATGCTCAGAGATCC	CAGGAAACAGCTATGACCGAGCTTTCGTTTGAAGCAG
10-3	TGTAACACGACGGCCAGTCAAGAAAGCAGATTTGGCAG	CAGGAAACAGCTATGACCTTCTCTCTTGGAAGGCTAGG
10-4	TGTAACACGACGGCCAGTGAGCCAAGAAGAGTAACAAGCC	CAGGAAACAGCTATGACCTTGTCTTCTTAAGGACCCAGAG
10-5	TGTAACACGACGGCCAGTGCAGAATACATTCAAGGTTTCAAG	CAGGAAACAGCTATGACCTCATTAATACTGGAAGCCACTTC

10-6	TGTA AACGACGGCCAGTACAGTGAGCACAATT AGCCG	CAGGAAACAGCTATGACCAAGCAGGGAAGCT CTTCATC
10-7	TGTA AACGACGGCCAGTGGAGTCCTAGCCCTT TCACC	CAGGAAACAGCTATGACCTGCTCCCCAAAAGC ATAAAC
11	TGTA AACGACGGCCAGTAATCCAGTCCTGCCA ATGAG	CAGGAAACAGCTATGACCAATGCAAAGGACA CCACACA
12	TGTA AACGACGGCCAGTTTAAAAGGTGTTTCAGC TAGAACTTG	CAGGAAACAGCTATGACCGGACAAGAACCAA GGCTCC
13	TGTA AACGACGGCCAGTTTGTGTATCATAGATT GATGCTTTTG	CAGGAAACAGCTATGACCGCAATAAAAAGTGTA TAAATGCCTG
14	TGTA AACGACGGCCAGTTCTGATCTCTCTGACA TGAGCTG	CAGGAAACAGCTATGACCACACCAAGACTCCC TCATCC
15	TGTA AACGACGGCCAGTAATTCTTAACAGAGAC CAGAACTTTG	CAGGAAACAGCTATGACCTGACAATACCTACAT AAAACCTCTTTCC
16	TGTA AACGACGGCCAGTCACTTTAAATAGTTCC AGGACACG	CAGGAAACAGCTATGACCCGCCTCATGTGGTT TTATGC
17	TGTA AACGACGGCCAGTTCCAGATTGATCTTG GGAGTG	CAGGAAACAGCTATGACCTGGTAACTCAGACT CAGCATCAG
18	TGTA AACGACGGCCAGTAGGGAAGGACCTCTC CTCTG	CAGGAAACAGCTATGACCGGTGCATTGATGGA AGGAAG
19	TGTA AACGACGGCCAGTTGTCTGCTCCACTTC CATTG	CAGGAAACAGCTATGACCTGGAATACAGAGTG GTGGGG
20	TGTA AACGACGGCCAGTGCAGCAGAAATCATC AGGTG	CAGGAAACAGCTATGACCTTCAGCAATCTGAG GAACCC
21	TGTA AACGACGGCCAGTACCATTGTCTTTTG AGCAG	CAGGAAACAGCTATGACCATGGAGTCTTTTG CACAGG
22	TGTA AACGACGGCCAGTTGAAGTGACAGTTCC AGTAGTCC	CAGGAAACAGCTATGACCAAACCAAACCCATG CAAAAG
23	TGTA AACGACGGCCAGTAGGACCCTGGAGTCG ATTG	CAGGAAACAGCTATGACCAAATAATGAATCAG CATCTTGCTC
<b>BRCA2</b>		
2	TGTA AACGACGGCCAGTAATGCATCCCTGTGTA AGTGC	CAGGAAACAGCTATGACCAGCAACACTGTGAC GTACTGG
3	TGTA AACGACGGCCAGTTGCCTTAACAAAAGTA ATCCATAGTC	CAGGAAACAGCTATGACCGATTTGCCCAGCAT GACAC
4	TGTA AACGACGGCCAGTAAACACTTCCAAAGA ATGCAAA	CAGGAAACAGCTATGACCTCTACCAGGCTCTT AGCCAAA
5/6	TGTA AACGACGGCCAGTCCAGCAGCTGAAATT TGTGAG	CAGGAAACAGCTATGACCTCTCAGGGCAAAG GTATAACG
7	TGTA AACGACGGCCAGTAGCGTTATACCTTTG CCCTG	CAGGAAACAGCTATGACCTTGACACCACTGGA CTACCAC
8	TGTA AACGACGGCCAGTTTCACTGTGTTGATTG ACCTTTC	CAGGAAACAGCTATGACCGACAGCAGAGTTTC ACAGGAAG
9	TGTA AACGACGGCCAGTTCCATTTCCATTTTC TTTCC	CAGGAAACAGCTATGACCTCACGACCATTTGA GACCAG
10-1	TGTA AACGACGGCCAGTTGTTTCTATGAGAAAG GTTGTGAGA	CAGGAAACAGCTATGACCACAGGCCAAAGAC GGTACAA
10-2	TGTA AACGACGGCCAGTGGAACCAAATGATAC TGATCC	CAGGAAACAGCTATGACCTTTCCAGTCCACTT TCAGAGG
10-3	TGTA AACGACGGCCAGTGTGGCTTCTTCATT CAGGG	CAGGAAACAGCTATGACCCAGAAGGAATCGTC ATCTATAAAAC
11-A	TGTA AACGACGGCCAGTCACTGTGCCCAAACA CTACC	CAGGAAACAGCTATGACCGCACATACATCTTG ATTCTTTTCC

11-B	TGTA AACGACGGCCAGTCAAGGATGTTCTGTCA AACCTAGTC	CAGGAAACAGCTATGACCTTGGACCTAAGAGT CCTGCC
11-C	TGTA AACGACGGCCAGTAAAGTAGCTAATGAAA GGAATAA	CAGGAAACAGCTATGACCGTAAATGTGCAGAT ACAGTATTA
11-D	TGTA AACGACGGCCAGTACAAATGGGCAGGAC TCTTAGGTC	CAGGAAACAGCTATGACCGATCAGCATCTCTG CATTCCCTCAGAAG
11-E	TGTA AACGACGGCCAGTCAGATGTTATTTTCCA AGCAGG	CAGGAAACAGCTATGACCCCCCTAAACCCAC TTCATT
11-F	TGTA AACGACGGCCAGTGAGGAATGCAGAGAT GCTGA	CAGGAAACAGCTATGACCTTGAATCACTGCCA TCAAATTC
11-G	TGTA AACGACGGCCAGTTCTTCAAGTAAATGTC ATGATTCTG	CAGGAAACAGCTATGACCTCCATTTTGTCTTT CTTATGTCAG
11-H	TGTA AACGACGGCCAGTGCCAGTTTATGAAGG AGGG	CAGGAAACAGCTATGACCGTCACTAGTTGATT TCCAGTACC
11-I	TGTA AACGACGGCCAGTTCAGACTGCAAGTGG GAAAA	CAGGAAACAGCTATGACCAAGTTGCAGGACTT TTTGCTG
11-J	TGTA AACGACGGCCAGTAAAACCTGTTTCTAT TGAGACTGTG	CAGGAAACAGCTATGACCCAGTTTGTGGGTAT GCATTTG
11-K	TGTA AACGACGGCCAGTAATGATTCAGGATATC TCTCAA	CAGGAAACAGCTATGACCACTTTCTCCAATCC AGACATAT
11-L	TGTA AACGACGGCCAGTGGCCACCTGCATTTA GGATA	CAGGAAACAGCTATGACCTTGCGTTTTGTAA TGAAGCA
11-M	TGTA AACGACGGCCAGTTGCCAAACGAAAATT ATGGC	CAGGAAACAGCTATGACCAGATGAATTTACCA CATTATATG
11-N	TGTA AACGACGGCCAGTGCTTCATAAGTCAGTC TCATCTGC	CAGGAAACAGCTATGACCGCTCTGGGTTTCT CTTATC
11-O	TGTA AACGACGGCCAGTAATACTGCTATACGTA CTCCAGA	CAGGAAACAGCTATGACCCAAAACATGAATG TTCTCA
11-P	TGTA AACGACGGCCAGTTTCACCTACGTCTAGA CAAAATGTATC	CAGGAAACAGCTATGACCACACTTTAAAAATA GTGATTGGCAAC
12	TGTA AACGACGGCCAGTCTGACTTTACTCTTTC AAACATTAGG	CAGGAAACAGCTATGACCAAATGCTCTTTTAG GTCCTCAGT
13	TGTA AACGACGGCCAGTTGCTGATTCTGTGTG ATGCTTG	CAGGAAACAGCTATGACCTTGGCTTCCAACT TTTGTG
14	TGTA AACGACGGCCAGTATGAGGGTCTGCAAC AAAGG	CAGGAAACAGCTATGACCGGGAAAACCATCA GGACATT
15	TGTA AACGACGGCCAGTGCCTCAGCCTGCTGA ATA	CAGGAAACAGCTATGACCCATTCCTGCACTA ATGTGTTT
16	TGTA AACGACGGCCAGTTTGGTAAATTCAGTT TTGGTTTG	CAGGAAACAGCTATGACCGAGAAGAAAGAGG GATGAGGG
17	TGTA AACGACGGCCAGTACCATGCTCAGCAAT GAAG	CAGGAAACAGCTATGACCCACTGACAACGGC TTGTGC
18	TGTA AACGACGGCCAGTGTTTAAACAGTGGAAT TCTAGAGTCA	CAGGAAACAGCTATGACCCAGTACATCTAAGA AATTGAGCATCC
19	TGTA AACGACGGCCAGTGGCAGTTCTAGAAGAA TGAAACTC	CAGGAAACAGCTATGACCGGCAAGAGACCGA AACTCC
20	TGTA AACGACGGCCAGTGCCTGGCCTGATACA ATTAAC	CAGGAAACAGCTATGACCTGTCCCTTGTGTGCT ATTCTTTG
21	TGTA AACGACGGCCAGTTGCTTGGTTCTTTAGT TTTAGTTGC	CAGGAAACAGCTATGACCCCTTGAATAATCATC AAGCCTCA
22	TGTA AACGACGGCCAGTGCTCTAATTTTGTGTG ATTTGTCCTG	CAGGAAACAGCTATGACCAATCATTTTGTGTAGT AAGGTCATTTT
23/24	TGTA AACGACGGCCAGTGCAAAATCCACTACTA ATGCC	CAGGAAACAGCTATGACCTGCCAACTGGTAGC TCCAAC

25	TGTAACGACGGCCAGTAAAGCAACAGGTCATT TTGGAA	CAGGAAACAGCTATGACCCCCATCTCCTGAG GTTTCAT
26	TGTAACGACGGCCAGTTCCCTATCAGCTAGAT TCCCC	CAGGAAACAGCTATGACCCCAGAGTTTCATA TCTTGCTTC
27-1	TGTAACGACGGCCAGTTAGGGGAGGGAGACT GTGTG	CAGGAAACAGCTATGACCACCAGACAAAAGA GCTTGGG
27-2	TGTAACGACGGCCAGTACAGAAGGCATTTC GCCAC	CAGGAAACAGCTATGACCAAACGCTGAGGTAA ATTTGAAAC

Blue = 5' tails for forward primers taken from the M13 bacteriophage genome.<sup>21,22</sup> Red = 5' tails for reverse primers taken from the M13 bacteriophage genome.<sup>21,22</sup>

## Appendix 2: Nested primers for sequencing selected exons of the *BRCA1* and *BRCA2* genes

Exon	Primer	Sequence
<b><i>BRCA1</i></b>		
6	Internal reverse	GAAGAAGAAAACAAATGG
8	Internal forward	ACCCTTTTAATTAAGAAA
<b><i>BRCA2</i></b>		
3	Internal forward	GATTTAGGACCAATAAG
9	Internal reverse	CAACAACAACAAAAAACC
10-3	Internal reverse	GTACTATTTACAAAAA
13	Internal reverse	GGAAGTGTTAACTTCT
15-1	Internal forward	GCTAAGTATTTATCTTTG
15-1	Internal reverse	CCATCAGTATTGTAGAC

## Appendix 3: *BRCA1* and *BRCA2* gene variants\* detected in 20 DNA samples

Mutation	Protein	Mutation type	Variant class <sup>†</sup>	Clinical importance <sup>‡</sup>	Detection method	Count <sup>§</sup>
<b><i>BRCA1</i></b>						
c.140G>A	p.Cys47Tyr	Missense	DM	-	MPS	1
c.212+1G>T	Intronic	IVS	DM	Yes	MPS	1
c.213-11T>G	Intronic	IVS	DM	Yes	MPS	1
c.1067A>G	p.Gln356Arg	Missense	DP	Unknown	MPS	3
c.1175_1214del40	p.Leu392GlnfsX5	Frame-shift	DM	Yes	MPS	1
c.2077G>A	p.Asp693Asn	Missense	DP	No	MPS	2
c.2082C>T	p.Ser694Ser	Synonymous	-	Unknown	MPS	9
c.2311T>C	p.Leu771Leu	Synonymous	-	Unknown	MPS	9
c.2315T>C	p.Val772Ala	Missense	DM	Unknown	MPS	1
c.2612C>T	p.Pro871Leu	Missense	DFP	No	MPS	8
c.2612delCinsTT	p.Pro871LeufsX32	Frame-shift	DM	-	MPS	1
c.3113A>G	p.Glu1038Gly	Missense	DP	No	MPS	9
c.3119G>A	p.Ser1040Asn	Missense	DM?	Unknown	MPS	1
c.3548A>G	p.Lys1183Arg	Missense	DP	No	MPS	9
c.3706_3707delAA	p.Asn1236TyrfsX7	Frame-shift	DM	Yes	MPS	1



c.3756_3759delGTCT	p.Ser1253ArgfsX10	Frame-shift	DM	Yes	MPS	1
c.4065_4068delTCAA	p.Asn1355LysfsX10	Frame-shift	DM	Yes	MPS	1
c.4308T>C	p.Ser1436Ser	Synonymous	-	Unknown	MPS	9
c.4837A>G	p.Ser1613Gly	Missense	DM?	No	MPS	9
<b>BRCA2</b>						
c.68-7T>A	Intronic	IVS	DM	Unknown	MPS	1
c.865A>C	p.Asn289His	Missense	DP	No	MPS	1
c.1114A>C	p.Asn372His	Missense	DFP	C>A	MPS	11
c.1365A>G	p.Ser455Ser	Synonymous	-	No	MPS	1
c.1395A>C	p.Val465Val	Synonymous	-	Unknown	MPS	1
c.1813dupA	p.Ile605AsnfsX11	Frame-shift	DM	Yes	HP kit	1
c.1938C>T	p.Ser646Ser	Synonymous	-	No	MPS	1
c.2229T>C	p.His743His	Synonymous	-	No	MPS	1
c.2957dupA	p.Asn986LysfsX2	Frame-shift	DM	Yes	HP kit	1
c.2971A>G	p.Asn991Asp	Missense	DM?	No	MPS	1
c.3396A>G	p.Lys1132Lys	Synonymous	-	No	MPS	10
c.3807T>C	p.Val1269Val	Synonymous	-	No	MPS	5
c.4478_4481delAAAG	p.Glu1493ValfsX10	Frame-shift	DM	Yes	MPS	1
c.7242A>G	p.Ser2414Ser	Synonymous	-	No	MPS	6
c.7655_7658delTTAA	p.Ile2552ThrfsX95	Frame-shift	DM	Yes	MPS	1
c.7762_7764delATAinsTT	p.Ile2588PhefsX60	Frame-shift	DM	-	MPS	1
c.7806-14T>C	Intronic	IVS	-	Unknown	MPS	17
c.7977-1G>C	Intronic	IVS	DM	Yes	MPS	1
c.8149G>T	p.Ala2717Ser	Missense	DM?	No	MPS	1
c.8297delC	p.Thr2766AsnfsX11	Frame-shift	DM	Yes	MPS	1
c.8575delC	p.Gln2859LysfsX4	Frame-shift	DM	Yes	MPS	1
c.9257-16T>C	Intronic	IVS	-	Unknown	MPS	1
c.9976A>T	p.Lys3326X	Nonsense	DP	No	MPS	1

DM = disease-causing mutation; - = not reported; MPS = massively parallel sequencing; IVS = intervening sequence; DP = disease-associated polymorphism; DFP: disease-associated polymorphism with additional supporting functional evidence; DM? = potential disease-causing mutation; C>A = reported as base pair change from cytosine to adenine; HP = homopolymer.

<sup>a</sup> Variants are named according to Human Genome Variation Society nomenclature, Version 2.0.<sup>23</sup>

<sup>†</sup> According to the Human Genome Mutation Database (BIOBASE HGMD<sup>®</sup> Professional, BIOBASE Biological Databases, Beverly, Massachusetts, USA) in February 2013.<sup>35</sup>

<sup>‡</sup> According to the 2014 Breast Cancer Information Core database.<sup>34</sup>

<sup>§</sup> Number of times the variant was observed in the DNA samples.

#### Appendix 4: Cost-efficiency of massively parallel sequencing/homopolymer mutation screening strategy for *BRCA1* and *BRCA2* genes

	Sanger sequencing	Multiplexing five samples sequenced by MPS	Savings
Cost per sample in NZD	2,700	820	1,880
Time per sample in minutes	510	284	226

NZD = New Zealand Dollars; MPS = massively parallel sequencing.